SwissNOS GluGlio
|
Title in German |
Glutamat Signalhemmer für neu diagnostiziertes Glioblastom: eine randomisierte, offene, multizentrische Phase IB/II Studie |
|
Title in English |
A phase Ib/II randomized, open label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma (GLUGLIO) |
|
Phase/Biobank/ect. |
Ib/II |
|
Description |
The study examines the effectiveness of a combination of the study drugs gabapentin, sulfasalazine and memantine together with standard therapy (radiotherapy and chemotherapy with temozolomide). All three study drugs inhibit the glutamate signaling pathway at different points. Glutamate is a messenger substance found in the human brain that is released by both glioblastoma cells and brain cells. Glutamate promotes the growth and invasion of glioblastoma cells into healthy brain tissue. This is intended to be prevented by additional administration of the three study drugs. |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Status |
open for patient recruitment: 01.05.2023 |
|
BASEC Nummer |
BASEC2022-01877 |
|
KOFAM |
SNCTP000005305 |
|
EudraCT No. |
NCT05664464 |
|
Insel-Nummer |
5419 |
Philogen IL 12L 19L 19-01 DODEKA
|
Title in German |
Eine Phase I Studie zur Beurteilung der Sicherheit und frühen Anzeichen der Wirksamkeit des humanen monoklonalen Antikörper-Zytokin Fusionsproteins IL12-L19L19 |
|
Title in English |
A phase I study to evaluate safety and early signs of efficacy of the human monoclonal antibody-cytokine fusion protein IL12-L19L19 |
|
Description |
We are interested in determining whether the investigational drug IL12-L19L19 is tolerated by patients suffering from certain types of advanced/metastatic solid tumors and whether early signs of efficacy can be observed. The active principle of the investigational drug is IL12-L19L19. IL12-L19L19 is a protein composed of two components, the L19 antibody and the anticancer drug IL12. It has the following properties: IL12 is the abbreviation for the cytokine “Interleukin 12”. IL12 stimulates cell-mediated immune defense and therefore has some anticancer activity. L19 is an antibody that selectively binds to a region of the protein fibronectin called “extradomain B” (EDB). EDB is only present in newly formed blood vessels and is therefore present in large quantities in most solid tumors. The property of L19 to accumulate exclusively in tumors has been described in the specialist literature and has been demonstrated using various methods such as histological analyses, animal experiments and clinical studies. The investigational drug in this study, IL12-L19L19, consists of IL12, which is coupled to part of the L19 antibody so that the drug accumulates exclusively in tumors. We assume that a prolonged anticancer effect and an increased concentration of IL12 directly in the tumor can be achieved along with fewer and weaker side effects. In this clinical study, the investigational drug is being tested on humans for the first time and the safety and tolerability of the drug are being investigated. Patients suffering from advanced/metastatic solid tumors and whose disease has progressed following therapy with immune checkpoint inhibitors can take part in this clinical study. It is a requirement that you have received immune checkpoint inhibitor treatment before this study and that the cancer has responded. All patients must be between 18 and 80 years old. Previous therapies may include chemotherapy, immunotherapy, or radiation therapy, but these therapies must be completed at least 4 weeks before the first administration of the investigational drug. Patients with primary brain tumors are not allowed to participate. |
|
Phase |
1 |
|
Head Clinical Trial |
|
|
Study Nurse |
|
|
Study Nurse |
|
|
Status |
open for patient recruitment: 20.05.2025 |
|
BASEC-Nummer |
2020-00433 |
|
WHO-Register-Nummer |
2019-000613-36 |
|
Insel-Nummer |
5576 |
RADIODOSE CAAA617A12101
|
Title in German |
Eine Studie zur Strahlendosimetrie, Sicherheit und Verträglichkeit der erweiterten Lutetium (177Lu) Vipivotide Tetraxetan-Behandlung bei chemo-naiven Erwachsenen mit metastasiertem kastrationsresistentem Prostatakrebs: RADIOpharmazeutische DOSimetrie-Bewertung (RADIODOSE) Studie |
|
Title in English |
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study (RADIODOSE) |
|
Description |
|
|
Phase |
I |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
open for patient recruitment |
|
BASEC number |
2024-01294 |
|
Kofam number |
HumRes67166 |
|
WHO registry number |
NCT06531499 |
|
Insel number |
6069 |